RESUMO
Tumor-associated antigens (TAAs) are potential targets for T cell-based immunotherapy approaches in cutaneous melanoma. BNT111, an investigational lipoplex-formulated mRNA-based therapeutic cancer vaccine encoding melanoma TAAs NY-ESO-1, tyrosinase, MAGE-A3, and TPTE, is undergoing clinical testing in adults. Expression of these TAAs in pediatric melanoma is unclear but is a prerequisite for feasibility of this treatment approach in children with melanoma. Our main objective was to characterize expression of those TAAs in pediatric melanomas compared to control cohorts. In this retrospective case control study, protein and transcript expression of NY-ESO-1, tyrosinase, MAGE-A3, and TPTE were analyzed in a cohort of 25 pediatric melanomas, 31 melanomas of young adults, 29 adult melanomas, and 30 benign melanocytic nevi in children using immunohistochemical staining and digital pathology (QuPath) and reverse transcription quantitative PCR. Based on IHC analysis, pediatric melanomas expressed tyrosinase (100.0%), TPTE (44.0%), MAGE-A3 (12.0%), and NY-ESO-1 (8.0%). Young adult melanomas expressed tyrosinase (96.8%), NY-ESO-1 (19.4%), MAGE-A3 (19.4%), and TPTE (3.2%). Adult melanomas expressed tyrosinase (86.2%), MAGE-A3 (75.9%), NY-ESO-1 (48.3%), and TPTE (48.3%). Childhood melanocytic nevi only expressed tyrosinase (93.3%). Expression prevalence of individual TAAs did not differ between subtypes of pediatric melanoma, and no association with prognosis was found. All four TAAs were expressed in pediatric melanoma, albeit NY-ESO-1 and MAGE-A3 to a lesser extent than in adult melanoma. These data support the possibility of investigating vaccines targeting these TAAs for the treatment of pediatric melanoma.
RESUMO
BACKGROUND: To evaluate the success of a breast augmentation, it is essential to measure outcomes from the patient perspective since a successful aesthetic result is especially determined by the patient. This study aimed to evaluate patient-reported satisfaction with their breasts, psychosocial, physical, and sexual well-being in patients undergoing breast augmentation using validated questionnaires. METHODS: This is a multicenter cohort study based on ongoing routinely-collected data. Patient-reported satisfaction and health-related quality of life were assessed with the BREAST-Q Augmentation Module at intake and six months postoperatively. RESULTS: A total of 1405 patients were included. Large changes in BREAST-Q scores (range, 0-100) between intake and six months postoperatively were seen: satisfaction with their breasts (mean, effect size: +57, 3.8), psychosocial well-being (+38, 2.1), physical well-being (-14, -1.2), and sexual well-being (+44, 2.4). Moreover, improvements in all four scales were not dependent on their intake scores and all postoperative scores reached similar levels. A decreased physical well-being of the chest was measured post-surgery. The satisfaction with the breasts scale correlated moderately to strongly with the psychosocial and sexual well-being scale 6 months post-surgery. Subgroup analysis based on patient characteristics found no differences in outcomes, except for BMI. CONCLUSION: Significant improvement in patient-reported satisfaction with their breasts, psychosocial, and sexual well-being can be seen six months after breast augmentation despite a declined physical well-being after treatment. Postoperative satisfaction levels do not depend on preoperative scores. These insights can contribute to improve preoperative communication between surgeon and patient regarding the expected outcomes.
